NCT07725705

SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL)

← Hub

Registry fields

Overall status: NOT_YET_RECRUITING
Conditions: PTCL, First Line Treatment
Study type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: SHR2554 combined with Liposomal Mitoxantrone
Lead sponsor: Institute of Hematology & Blood Diseases Hospital, China (OTHER)

Cached at: 2026-07-25 04:09:43

View on ClinicalTrials.gov

Brief summary

This is a single-arm, multicenter, Phase Ib/IIa study designed to explore the efficacy and safety of SHR2554 in combination with liposomal mitoxantrone for the treatment of patients with treatment-naive peripheral T-cell lymphoma (PTCL). The study is divided into a Phase Ib safety lead-in phase and a Phase IIa dose expansion phase.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report